Retinoid compounds which act specifically or selectively on RAR
&agr;
receptor subtypes in preference over RAR
&bgr;
and RAR
&Ggr;
receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
作用于
RARα亚型的
视黄酸类化合物,具有优于
RARβ和
RARγ亚型的选择性或特异性,具有与
视黄酸相关的理想药物特性,特别适用于治疗肿瘤,如急性单核细胞白血病、宫颈癌、骨髓瘤、卵巢癌和头颈癌,而不具有
视黄酸的一个或多个不良副作用,如诱导体重减轻、粘膜皮肤毒性、皮肤刺激和致畸性。